Biotech Values

[mcbio]

Re: ACHN-addendum re ACH-1625 data

Addendum re ACH-1625 data in #msg-50044485: It’s curious that the control arms in all four cohorts showed a reduction in viral load of 0.22-0.29 logs* after five days of “dosing” with nothing but a sugar pill. Insofar as VL measurements are empirical rather than subjective, I find it surprising that all four cohorts showed a placebo benefit and that the placebo VL reductions fell within a tight range.

Perhaps ANDS can license the sugar pill and declare it has a robust HCV pipeline?

In all seriousness, you're not suggesting that the control arm response should lead one to view the ACH-1625 data suspiciously are you? I assume not, but just want to confirm.